Idiopathic Pulmonary Fibrosis Clinical Trial
— QUALY-IPF-PPPOfficial title:
Prospective, Observational Study of the Factors Affecting Patient and Physician Perceptions of Quality of Life in Idiopathic Pulmonary Fibrosis (IPF)
This study aims to evaluate the differences between patient's and their physicians' perception of quality of life and the effect of disease severity and co-morbidities. Patients and physicians will complete two sets of questionnaires at an initial clinic visit and again six months later.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | July 1, 2020 |
Est. primary completion date | March 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with a multidisciplinary diagnosis of IPF according to the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guidelines. - All ranges of disease severity based on pulmonary function testing: forced vital capacity (FVC) and diffusing capacity (DLCO). Exclusion Criteria: - Any impairment or co-morbid disease that results in an inability to read or understand a questionnaire or provide informed consent. The study team member will make this determination according to their best clinical judgement. - The questionnaires will be administered in English language only and thus this study will be conducted in patients who are able to read, write, and speak English language. |
Country | Name | City | State |
---|---|---|---|
United States | University of Washington - Center for Interstitial Lung Disease | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | Washington Research Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient and Physician Responses to the Kings Brief ILD (K-BILD) Questionnaire | A comparison of physician and patient reported quality of life based on responses to the Kings Brief ILD Questionnaire (K-BILD). The domain and total score ranges are 0-100 where a score of 100 represents best health status. | 6 months | |
Primary | Patient and Physician Responses to the EuroQol five dimensional 5-Level (EQ-5D-5L) questionnaire | A comparison of physician and patient reported quality of life based on responses to the EuroQol five dimensional 5-Level (EQ-5D-5L) questionnaire. The domain ranges are 1-5 and the total score ranges are 5-25 where a score of 5 represents best health status. The visual analog scale portion of the questionnaire ranges from 0 to 100 where a score of 100 represents best health status. | 6 months | |
Primary | Patient and Physician Responses to the Raghu Quality of Life in Interstitial Lung Disease (RQ-LIFE-ILD) Questionnaire | A comparison of physician and patient reported quality of life based on responses to a novel visual analog scale questionnaire the Raghu Quality of Life in Interstitial Lung Disease (RQ-LIFE-ILD) Questionnaire. The domain ranges are 0 to 10 and the total score ranges are 0 to 50 where a score of 0 represents best health status. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
Completed |
NCT00540475 -
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
|